Eiger nabs the first FDA ap­proval for Prog­e­ria, an ul­tra-rare pre­ma­ture ag­ing dis­ease, with an old Mer­ck drug

Eiger Bio­Phar­ma­ceu­ti­cals $EIGR has re­ceived an FDA OK for a drug Mer­ck li­censed to them at no cost — and now re­port­ed­ly plans to charge a lev­el con­sis­tent with oth­er ul­tra-rare dis­ease med­i­cines.

The biotech an­nounced Fri­day evening that reg­u­la­tors had ap­proved lon­a­farnib for the treat­ment of Hutchin­son-Gil­ford prog­e­ria syn­drome, al­so known as Prog­e­ria, as well as some progeroid laminopathies in chil­dren old­er than one year. It’s the first ap­proval grant­ed for the con­di­tion, and the drug will be mar­ket­ed and sold as Zok­in­vy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.